Decibel-full color-CMYK.png
Decibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Update
10. August 2022 16:30 ET | Decibel Therapeutics, Inc.
- Announced positive data from interim analysis of Phase 1b clinical trial of DB-020 in patients receiving cisplatin chemotherapy; data support continued development of DB-020 as a potential therapy...
Decibel-full color-CMYK.png
Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy
28. Juni 2022 07:00 ET | Decibel Therapeutics, Inc.
- 87% of patients who experienced ototoxicity in their placebo-treated ear were protected from ototoxicity in their DB-020-treated ear – - Data support continued development of DB-020 as a potential...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
03. Juni 2022 07:30 ET | Decibel Therapeutics, Inc.
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
17. Mai 2022 07:30 ET | Decibel Therapeutics, Inc.
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
02. Mai 2022 07:30 ET | Decibel Therapeutics, Inc.
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel-full color-CMYK.png
Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18. März 2022 07:00 ET | Decibel Therapeutics, Inc.
- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research...
Decibel-full color-CMYK.png
Decibel Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
10. Februar 2022 16:30 ET | Decibel Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel-full color-CMYK.png
Decibel Therapeutics Reports on Continued Progress of Lead Gene Therapy Product Candidate DB-OTO and Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression Across Gene Therapy Pipeline
09. Februar 2022 18:00 ET | Decibel Therapeutics, Inc.
- Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging studies with expression analysis, functional recovery and tolerability...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the 45th Annual Association for Research in Otolaryngology (ARO) Meeting
31. Januar 2022 07:00 ET | Decibel Therapeutics, Inc.
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel-full color-CMYK.png
Decibel Therapeutics to Present at the H.C. Wainwright BioConnect Conference
04. Januar 2022 07:00 ET | Decibel Therapeutics, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...